These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35920868)

  • 21. Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge.
    Bartalucci C; Limongelli A; Nicolini LA; Ponzano M; Tigano S; Farinella ST; Carrega G; Malerba G; Magnè F; Balletto E; Giacobbe DR; Riccio G; Cenderello G; Taramasso L; Bruzzone B; Vena A; Di Biagio A; Mikulska M; De Maria A; Dentone C; Bassetti M
    J Chemother; 2024 Jul; 36(4):283-290. PubMed ID: 38095569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
    Passariello M; Ferrucci V; Sasso E; Manna L; Lembo RR; Pascarella S; Fusco G; Zambrano N; Zollo M; De Lorenzo C
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies.
    Vellas C; Del Bello A; Gaube G; Tremeaux P; Jeanne N; Ranger N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac093. PubMed ID: 35299988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Casirivimab/Imdevimab: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
    Tuccori M; Convertino I; Ferraro S; Cappello E; Valdiserra G; de Luca G; Franchini M; Focosi D
    Expert Opin Drug Discov; 2022 Jun; 17(6):531-546. PubMed ID: 35361043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
    J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
    Buonomo AR; Filippo ID; Esposito N; Saccone G; Nobile M; Viceconte G; Villari R; Carlo CD; Bifulco G; Gentile I
    Am J Perinatol; 2024 Feb; 41(3):365-367. PubMed ID: 37072016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study.
    Rhudy C; Bochenek S; Thomas J; St James G; Zeltner M; Platt T
    Am J Health Syst Pharm; 2023 Jan; 80(3):130-136. PubMed ID: 36264659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.
    Cicchitto G; Cardillo L; de Martinis C; Sabatini P; Marchitiello R; Abate G; Rovetti A; Cavallera A; Apuzzo C; Ferrigno F; Fusco G
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous REGEN-COV antibody administration in a community pharmacy.
    Dougherty TS; McBride J; Barnett CL; Gabriel WM
    J Am Pharm Assoc (2003); 2023; 63(3):961-966. PubMed ID: 36710148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune treatment in COVID-19.
    Menéndez R; González P; Latorre A; Méndez R
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):59-63. PubMed ID: 35488829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes.
    Hayek S; Ben-Shlomo Y; Dagan N; Reis BY; Barda N; Kepten E; Roitman A; Shapira S; Yaron S; Balicer RD; Netzer D; Peretz A
    Nat Commun; 2022 Aug; 13(1):4480. PubMed ID: 35918340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection.
    Al-Obaidi MM; Gungor AB; Nematollahi S; Zangeneh TT; Bedrick EJ; Johnson KM; Low-Adegbija NE; Alam R; Rangan P; William Heise C; Ariyamuthu VK; Shetty A; Qannus AA; Murugapandian S; Ayvaci MMS; Anand PM; Tanriover B
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac186. PubMed ID: 35791354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19.
    Ruggeri M; Signorini A; Caravaggio S
    PLoS One; 2023; 18(2):e0279022. PubMed ID: 36763607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
    Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
    J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
    [No Abstract]   [Full Text] [Related]  

  • 38. Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database.
    Takemoto K
    Oncology; 2024; 102(3):195-205. PubMed ID: 37666220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
    Hooper AT; Somersan-Karakaya S; McCarthy SE; Mylonakis E; Ali S; Mei J; Bhore R; Mahmood A; Geba GP; Dakin P; Weinreich DM; Yancopoulos GD; Herman GA; Hamilton JD;
    mBio; 2022 Dec; 13(6):e0169922. PubMed ID: 36255239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.